Member Info for Seaking1

I think there were no figures given out as true binding Have been licensed to use chosourse and will pay as they use different parts of the chosourse platform. So it maybe impossible to give a number. Having said that I don’t know why it was not given out as an RNS .

True binding would have had to pay an upfront fee for the license which may have been in the 10s of thousands or 100 , just my thoughts. This share is a good hold for the next few years. I expect positive figures in the next two quarters. They did very well with the tie in with mammoth.
:-).

Sanofi Are under investigation re: man slaughter charge . Good they don’t have immunity from prosecution.

There is one thing that is as sure as chips are chips and that is curvacs sp will go up a good bit when they list in October . Look at the backers behind them, quality always shines through. Good business GSK.

Sanofi/ GSK. You meant Bruce.

Newbie ,
I would like to know we’re you heard that one from. The one thing with synairgen is they have a far better chance of bringing there product to market than any of the vaccine chasing companies.

I have shares in AstraZeneca and GlaxoSmithKline but I’m a realist and don’t expect a vaccine for another year at least . My personal preference is gsk to come up with one first working with either clover or Sanofi a . That’s were my big chunk of share dealing money is invested.

That would really let the floodgates open. To give immunity to a biopharma Company is asking for trouble big time . Old Donald would set up his own company giving you vaccines with chlorine in them and say it’s wonderful, you will have it and then he will laugh at you as you will have no redress. Yes we all know that’s a bit far fetched but you get my meaning.

Wouldn’t and shouldn’t get passed over here and definitely wouldn’t get approval in e.u. Vaccines take time . I think that the big vaccine companies have more of a chance of coming up with one over the next year. Having the government’s money is great as obviously it goes towards R&D for a covid vaccine.
I think some people think the money just goes into the companies pockets and isn’t spent.

I think you got your sentence back to front. I’m not old though, can still manage 60 miles a week on my bike. Another deal done.

Kernowlad, The way this share moves it would not surprise me if it did go back to 770 odd.
You would think with all the deals that they have which are non covid it would stay in a tighter range.
If AstraZeneca attempts at coming up with a vaccine bombs who knows were this sp will be.
Anything below 790 is a bargain in my view. Not that it will go back that far. Good weekend . I smashed the big 70 and am still young, especially in the head! Stay safe. :-)

Neither would I . :-(

Well I suppose the scientists may not know to much which follows on that all on this site me included no nothing , just what we read and copy and paste. :-)

Ha, ha, that gave me a chuckle. :-) good one.

Op warp speed indeed . It won’t happen with gsk Saphoni as they will take there time getting it right, rather than go into a phase two or three and fail.

Your point being.

I actually think this is a better buy than AstraZeneca but as they get more exposure I’m hoping the sp will go up a bit( more volatility ),. Oxford biomedica sp will probably be up near 850 I think by the end of the session. Just my thoughts.

Yes I agree, very good news. I will have to move my entry point up to about 810 now . I cannot buy right now as I’m in AstraZeneca, gsk, and synairgen.

Still slightly ahead in synairgen having already sold a few and put it into AstraZeneca. So if any go up I will be back in here. Hope you are well. Stay safe and make money. :-)

As I’ve said the recession has hardly started yet you will be looking at approx 8% of the workforce at least. I tasted the last large one in the seventies but missed most of it as I emigrated to Aussie best decision I ever made.

As we are starting a recession my thinking is that the likes of Uniliver will see sales drop so I’m hanging out for at least a drop to 43 although it may take awhile .

Excellent, thanks, I do like private equity firms just to scroll though the investments they have made .

This is typical of lse never quite on the ball , even without the covid problems.

That’s good thinking. I am trying to stick to biopharma/ healthcare and Unilever rather than trying to cover a broader market, but thanks anyway. Just got my fingers singed by selling standard chartered but you cannot win them all.

One area (not just becouse of standard) I will keep well away from is the banks.